Rankia Colombia Rankia Argentina Rankia Brasil Rankia Chile Rankia Czechia Rankia Deutschland Rankia España Rankia France Rankia Indonesia Rankia Italia Rankia Magyarország Rankia México Rankia Netherlands Rankia Perú Rankia Polska Rankia Portugal Rankia Romania Rankia Türkiye Rankia United Kingdom Rankia USA
Acceder

Farmas USA

135K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
13.742 / 16.979
#109929

Re: Farmas USA

Ana, por si estas con tiempo para bolsa...

Announces Updated Positive Interim Data at the 2018 Hemophilia Drug Development Summit

A ver si se nos mueven un poco que andan aburridisimas estos días...

Cbio

#109930

Re: Farmas USA

Mugi 

IDRA has visto su comportamiento despues del 1/5 RS y la fallida fusion .?

Yo las tenia a 7.20 pero precio pre r/s y me salto el stop a 5.40 y me olvide , no las mire mas crei que se iban a hundir que es lo tipico despues de un r/s

-----------

Idera Pharmaceuticals (NASDAQ: IDRA) resumed with Overweight rating and $15 (76% upside) price target at JPMorgan

https://seekingalpha.com/news/3383040-premarket-analyst-action-healthcare

#109931

Re: Farmas USA

Pues la verdad es que estando de vacaciones sigo sólo las que llevo y poco más...parece que puede tener un bonito rally

Idra

#109933

Re: Farmas USA

TGTX
RA CAPITAL (Peter Kolchinksy) increased his stake in $tgtx from 2.4 million shares to 4.2 million shares, a 73% increase on the latest 13F heading into crucial UNITY ORR data.

#109934

Re: Farmas USA

Patwin 

para mi esa es una de las razones por la que seria dificl responsabilizar 100 de las muertes a Nuplazid a menos que se haga un estudio muy costoso pero muy especial, aunque algo la FDA tiene que hacer pero lo cierto es que segun el Q2/ER las ventas aumentaron , entonce ... habria que ver 

#109935

Re: Farmas USA

Bonica vela dejo ayer , parece que se va a girar , ...igual luego me la compro unas puts para recoger profit en 2019 

---

Paratek Drugs Worth Betting On

Sizable Potential Addressable Market of Omadacycline

If the FDA approved Omadacycline, the launch is anticipated by the first quarter of 2019. Paratek has taken significant steps to prepare for a launch, such as building out sales and marketing infrastructure. In addition, it sold $140 million worth of Convertible Senior Subordinated Notes in April. This cash allows Paratek to position itself for the launch of Omadacycline, and ensure Paratek has cash until Q1 2021. According to Paratek, by 2028, the potential addressable US hospital market will reach $3.9B, and the potential addressable US community market will reach $5.4B. Hospital market refers to when patients are actually hospitalized and obtain prescribed drugs at the hospital, whereas community market refers to someone not admitted to the hospital (ex. ER, doctor's office, clinics, etc.). Therefore, Paratek has a total addressable market of $9.3B.

Strong Partnership with Bigger Firms

Paratek has partnered with established pharmaceutical companies to develop and market products for the larger community markets

https://seekingalpha.com/article/4196297-paratek-drugs-worth-betting

 

#109936

Re: Farmas USA

RGLS

vuelve a retomar su senda

-10%

Edit: -1% ya

EDIT: en verde ya

Brokers destacados